FS.COM
19.6.2020 10:02:08 CEST | Business Wire | Press release
FS.COM , a high-speed communication product and solution provider for data centers, enterprises, and telecom networks, collaborated with US Conec, a leader in providing passive components for high density optical interconnects, to supply MTP® brand cable assembly products for high density data center applications.
With the ever-growing demands on high speed networks, MTP® cabling systems are required to provide more connections in limited space applications. “Each FS MTP® cable uses US Conec's MTP® connectors to ensure stable and highly effective interconnections of MTP® cabling infrastructure in data center environments. US Conec's MTP® connectors are recognized as the industry leading high density cabling solution for low insertion loss, excellent optical performance and space saving advantages,” said Daniel Xiang, CEO of FS.COM. “In addition to MTP® cabling products, FS.COM has introduced ancillary products from the MTP® family including MTP® cleaners, MTP® adapters and field tools for MTP® PRO connector.”
MTP® cleaners
- Clean ferrules of MT based connectors with simple push for cabling assemblies and field installation
MTP® adapters
- Compatible with all US Conec MTP® brand connectors from 4 to 72 fibers for coupling and debris protection
Field tools for MTP® PRO connector
- Simple change of MTP® PRO cable polarity and pins in less than a minute
“We are excited to partner with FS.COM to deliver optical technology and connectivity solutions that will drive the next generation of communications infrastructure worldwide,” states Joe Graham, President of US Conec. “FS.COM has demonstrated strong market access and we feel that together we can deliver superior value to our collective customer base.”
MTP® is a registered trademark of US Conec Ltd.
About US Conec
US Conec is a global leader in the design and development of high-density optical interconnects. With nearly 30 years of innovative experience, the company provides industry leading components for data center and enterprise structured cabling, public networks, on-board optical interconnects, industrial and military markets worldwide. Key product developments include single-mode and multimode MT-style and custom multi-fiber ferrules, MTP® brand MPO connectors, MXC® connectors, PRIZM® LightTurn® and PRIZM® MT lensed ferrule technology, ELiMENT™ single fiber connector solutions, IBC™ brand fiber optic cleaning solutions, termination equipment for multi-fiber interconnects, and high precision optical packaging components. US Conec is headquartered in Hickory, North Carolina, and is an equity venture of three leading communication technology companies—Corning Optical Communications, Fujikura, and NTT-AT.
About FS.COM
FS.COM is a high-speed communication product and solution provider for connecting and securing global data center, enterprise, and telecom networks. FS.COM is dedicated to fulfilling product systems and tailoring project solutions for IT professionals with immediate services by developing its talents, labs and local service center. Through continuous technology innovation and brand partnership, FS products and solutions have served more than 300,000+ customers in over 200 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200619005075/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom